Literature DB >> 19759338

Intramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cells.

David Zisa1, Arsalan Shabbir, Michalis Mastri, Gen Suzuki, Techung Lee.   

Abstract

Skeletal muscle produces a myriad of mitogenic factors possessing cardiovascular regulatory effects that can be explored for cardiac repair. Given the reported findings that VEGF may modulate muscle regeneration, we investigated the therapeutic effects of chronic injections of low doses of human recombinant VEGF-A(165) (0.1-1 microg/kg) into the dystrophic hamstring muscle in a hereditary hamster model of heart failure and muscular dystrophy. In vitro, VEGF stimulated proliferation, migration, and growth factor production of cultured C2C12 skeletal myocytes. VEGF also induced production of HGF, IGF2, and VEGF by skeletal muscle. Analysis of skeletal muscle revealed an increase in myocyte nuclear [531 +/- 12 VEGF 1 microg/kg vs. 364 +/- 19 for saline (number/mm(2)) saline] and capillary [591 +/- 80 VEGF 1 microg/kg vs. 342 +/- 21 for saline (number/mm(2))] densities. Skeletal muscle analysis revealed an increase in Ki67(+) nuclei in the VEGF 1 microg/kg group compared with saline. In addition, VEGF mobilized c-kit(+), CD31(+), and CXCR4(+) progenitor cells. Mobilization of progenitor cells was consistent with higher SDF-1 concentrations found in hamstring, plasma, and heart in the VEGF group. Echocardiogram analysis demonstrated improvement in left ventricular ejection fraction (0.60 +/- 0.02 VEGF 1 microg/kg vs. 0.45 +/- 0.01 mm for saline) and an attenuation in ventricular dilation [5.59 +/- 0.12 VEGF 1 microg/kg vs. 6.03 +/- 0.09 for saline (mm)] 5 wk after initiating therapy. Hearts exhibited higher cardiomyocyte nuclear [845 +/- 22 VEGF 1 microg/kg vs. 519 +/- 40 for saline (number/mm(2))] and capillary [2,159 +/- 119 VEGF 1 microg/kg vs. 1,590 +/- 66 for saline (number/mm(2))] densities. Myocardial analysis revealed approximately 2.5 fold increase in Ki67+ cells and approximately 2.8-fold increase in c-kit(+) cells in the VEGF group, which provides evidence for cardiomyocyte regeneration and progenitor cell expansion. This study provides novel evidence of a salutary effect of VEGF in the cardiomyopathic hamster via induction of myogenic growth factor production by skeletal muscle and mobilization of progenitor cells, which resulted in attenuation of cardiomyopathy and repair of the heart.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19759338      PMCID: PMC2777764          DOI: 10.1152/ajpregu.00227.2009

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  66 in total

1.  HGF/SF is present in normal adult skeletal muscle and is capable of activating satellite cells.

Authors:  R Tatsumi; J E Anderson; C J Nevoret; O Halevy; R E Allen
Journal:  Dev Biol       Date:  1998-02-01       Impact factor: 3.582

Review 2.  Vascular protection: A novel nonangiogenic cardiovascular role for vascular endothelial growth factor.

Authors:  I Zachary; A Mathur; S Yla-Herttuala; J Martin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-06       Impact factor: 8.311

3.  IGFs, insulin, Shh, bFGF, and TGF-beta1 interact synergistically to promote somite myogenesis in vitro.

Authors:  A Pirskanen; J C Kiefer; S D Hauschka
Journal:  Dev Biol       Date:  2000-08-15       Impact factor: 3.582

4.  Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat--angiogenesis and angioma formation.

Authors:  E R Schwarz; M T Speakman; M Patterson; S S Hale; J M Isner; L H Kedes; R A Kloner
Journal:  J Am Coll Cardiol       Date:  2000-04       Impact factor: 24.094

5.  Reduced myocardial nerve growth factor expression in human and experimental heart failure.

Authors:  D M Kaye; G Vaddadi; S L Gruskin; X J Du; M D Esler
Journal:  Circ Res       Date:  2000-04-14       Impact factor: 17.367

Review 6.  Vascular endothelial growth factor (VEGF) and its receptors.

Authors:  G Neufeld; T Cohen; S Gengrinovitch; Z Poltorak
Journal:  FASEB J       Date:  1999-01       Impact factor: 5.191

Review 7.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

8.  Mesenchymal stem cells can be differentiated into endothelial cells in vitro.

Authors:  Joachim Oswald; Sabine Boxberger; Birgitte Jørgensen; Silvia Feldmann; Gerhard Ehninger; Martin Bornhäuser; Carsten Werner
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

9.  Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor.

Authors:  C Bauters; T Asahara; L P Zheng; S Takeshita; S Bunting; N Ferrara; J F Symes; J M Isner
Journal:  J Vasc Surg       Date:  1995-02       Impact factor: 4.268

10.  Vascular endothelial growth factor modulates skeletal myoblast function.

Authors:  Antonia Germani; Anna Di Carlo; Antonella Mangoni; Stefania Straino; Cristina Giacinti; Paolo Turrini; Paolo Biglioli; Maurizio C Capogrossi
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

View more
  27 in total

1.  Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair.

Authors:  David Zisa; Arsalan Shabbir; Michalis Mastri; Tyler Taylor; Ilija Aleksic; Mary McDaniel; Gen Suzuki; Techung Lee
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-09-30       Impact factor: 4.733

2.  Activation of host tissue trophic factors through JAK-STAT3 signaling: a mechanism of mesenchymal stem cell-mediated cardiac repair.

Authors:  Arsalan Shabbir; David Zisa; Huey Lin; Michalis Mastri; Gregory Roloff; Gen Suzuki; Techung Lee
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-09-17       Impact factor: 4.733

Review 3.  Genetic engineering of mesenchymal stem cells and its application in human disease therapy.

Authors:  Conrad P Hodgkinson; José A Gomez; Maria Mirotsou; Victor J Dzau
Journal:  Hum Gene Ther       Date:  2010-10-22       Impact factor: 5.695

4.  Host tissue response in stem cell therapy.

Authors:  Techung Lee
Journal:  World J Stem Cells       Date:  2010-08-26       Impact factor: 5.326

Review 5.  Small Vessels, Big Role: Renal Microcirculation and Progression of Renal Injury.

Authors:  Alejandro R Chade
Journal:  Hypertension       Date:  2017-02-13       Impact factor: 10.190

Review 6.  Rodent models of heart failure: an updated review.

Authors:  A C Gomes; I Falcão-Pires; A L Pires; C Brás-Silva; A F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

7.  Stem cell therapy independent of stemness.

Authors:  Techung Lee
Journal:  World J Stem Cells       Date:  2012-12-26       Impact factor: 5.326

Review 8.  Angiogenic cytokines in renovascular disease: do they have potential for therapeutic use?

Authors:  Alejandro R Chade; Nicholas Stewart
Journal:  J Am Soc Hypertens       Date:  2013-02-19

9.  Activation of Toll-like receptor 3 amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency.

Authors:  Michalis Mastri; Zaeem Shah; Terence McLaughlin; Christopher J Greene; Leah Baum; Gen Suzuki; Techung Lee
Journal:  Am J Physiol Cell Physiol       Date:  2012-07-25       Impact factor: 4.249

10.  Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repair.

Authors:  David Zisa; Arsalan Shabbir; Gen Suzuki; Techung Lee
Journal:  Biochem Biophys Res Commun       Date:  2009-10-15       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.